ArticleERJ open research2026
Development and validation of a parent-proxy bronchiectasis child quality-of-life instrument: the BC-QoL.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations.Journal of molecular medicine (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Quality of life (QoL), the highest prioritised outcome by children with bronchiectasis and their parents, is a patient-reported outcome measure increasingly considered essential when evaluating health and interventions. Despite this, there are no validated instruments that specifically measure QoL related to bronchiectasis in children. We aimed to develop and validate a new bronchiectasis child-specific parent-proxy QoL instrument (BC-QoL). Methods: We developed a draft 44-item BC-QoL and subsequently conducted a prospective cohort study in which 142 parents completed the draft BC-QoL and six other measures (two validated cough scores; the Parent-proxy Children's Acute Cough-specific QoL questionnaire; the Depression, Anxiety and Stress Scale - 21-items; the RAND-36; and the Pediatric Quality of Life Inventory (PedsQL™ 4.0)) to assess the convergent and discriminant validity of the BC-QoL. The questionnaires were completed over 3 weeks at different phases of a child's illness (stable state, exacerbation and/or recovery). Responses were analysed using psychometric and clinical impact techniques to reduce the number of items and determine the instrument's reliability and validity. The minimal important difference (MID) was also calculated. Results: The final 23-item BC-QoL instrument with its three domains (emotional, physical and social well-being) demonstrated high split-half reliability (0.95), Cronbach's alpha (0.97), repeatability (intraclass coefficient 0.74, 95% CI 0.62-0.82), validity and responsiveness. BC-QoL's domains significantly correlated with those of the PedsQL™ 4.0 (Spearman correlations: emotional=0.43, social=0.41, physical=0.47). BC-QoL's MID ranged from 0.74 to 1.32. Conclusion: This study provides evidence supporting the validity and reliability of BC-QoL. The BC-QoL can be used to evaluate the impact and effectiveness of interventions and better understand the disease burden among children with bronchiectasis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.